http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013150540-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
| filingDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013150540-A |
| titleOfInvention | KINASE MODULATION AND INDICATIONS FOR ITS USE |
| abstract | 1. A method of treating a subject suffering from a disease or condition mediated by Flt3, or at risk of developing such a disease or condition, comprising administering to said subject an effective amount of a compound having the chemical structure of Formula III of any of its salts, prodrugs, tautomers or isomers, where: L is —CH—, —CHCH—, —CH (R) -, —C (O) - or —C (O) NH—; R is selected from the group consisting of hydrogen, —OR, —CN, fluoro, chloro, lower alkyl substituted with fluorine lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, substituted with lower alkyl fluorine, —NHR, —NRR, —OR and —S (O) R; R is selected from the group consisting of hydrogen, C1-6alkyl, substituted by C1-6alkyl fluorine, OH, Calkoxy and substituted by C1-4 fluorine; R is heterocycloalkyl, heteroaryl, or in which Rk L is attached to Formula III, while heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents substituents selected from the group consisting of halogen, lower alkyl, substituted by fluorine lower alkyl, cycloalkylamino, -NHR, -NRR, -OR and -S (O) R; R, R, R, R and R are independently selected from the group consisting of hydrogen , halogen, lower alkyl, substituted by fluorine lower alkyl, cycloalkylamino, -NHS (O) R, -NHC (O) R, -NHR, -NRR, -OR and -S (O) R; R is selected from the group consisting of lower alkyl and fluorine-substituted lower alkyl; R is independently selected at each occurrence from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, with lower alkyl optionally |
| priorityDate | 2011-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.